CSL Limited is below $100: Time to buy shares?

With recent reinvestments in its core business, CSL Limited (ASX:CSL) will start to look attractive pretty soon.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

From its recent lofty highs of $120 earlier this year, shares in vaccine and blood product manufacturer CSL Limited (ASX: CSL) have dropped back below $100. With the company's recent investments in building capacity for the future, CSL appears to be in a solid position.

A number of recent developments have strengthened the investment case, in my opinion, with the recent debt reissue foremost among them. CSL recently launched a US$550 million private placement with a weighted average interest cost of 3%, and an average life of 12.5 years. Even with super-low interest rates globally, CSL's cost of debt is among the very lowest on the ASX.

This is important because as contributor Regan Pearson illustrated here, a significant chunk of the company's long term returns have come from (sustainably) high levels of debt.

Building manufacturing capacity

CSL is also developing a number of new facilities to boost the capacity of its business all throughout the supply chain. In addition to new production facilities in several countries, CSL is also expanding its packing facilities as well as its network of plasma collection centres. CSL's plasma collection network grew by 20% to 140 facilities throughout Europe and the USA in the past year.

All of these developments will improve the company's ability to maintain supply of its important products, as well as potentially increase efficiency and reduce operating costs. In addition to the ongoing turnaround of the Seqirus vaccine division the continued high spending on Research & Development (R&D) provides additional upside potential over the long term.

CSL is starting to look interesting as its shares drop below $100.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »